Keith A. Goldan sold $43k of SNDX
Chief Financial Officer at Syndax Pharmaceuticals Inc. 2,082 shares at an average of $20.62, traded Feb 6, 2026, filed Feb 6, 2026.
Score components
- +22RoleCFO
- +6Trade size$43k at market
- 0Share of holdings soldSold 1.4% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.0%, 3m +2.3%, 6m -2.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-041497, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 30, 2026 | JOther Common Stock | +1,219 | $8.48 | $10k | 93,671 | Feb 6, 2026 |
| Feb 4, 2026 | AGrant or award Common Stock | +21,500 | $0.00 | $0 | 115,171 | Feb 6, 2026 |
| Feb 4, 2026 | AGrant or award Common Stock | +30,750 | $0.00 | $0 | 145,921 | Feb 6, 2026 |
| Feb 6, 2026 | SOpen-market sale Common Stock | -2,082 | $20.62 | $43k | 143,839 | Feb 6, 2026 |
| Feb 4, 2026 | AGrant or award Stock Options (Right to buy)derivative | +118,000 | $20.43 | $2.4M | 118,000 | Feb 6, 2026 |
Related signals
Other insiders at Syndax Pharmaceuticals Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $785k 32,375 shares | -6% | |
| 40Moderate | Syndax Pharmaceuticals Inc | Nicholas A.J. Botwood Head of R&D, CMO | $1.2M 65,515 shares | -69% | |
| 37Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $22k 1,177 shares | -1% | |
| 51Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $130k 6,847 shares | -1% | |
| 38Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $72k 3,410 shares | -2% | |
| 48Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $361k 17,159 shares | -3% | |
| 44Moderate | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $153k 7,412 shares | -1% | |
| 25Weak | Syndax Pharmaceuticals Inc | Michael A Metzger Chief Executive Officer | $2.6M 157,307 shares | -34% | |
| 13Weak | Syndax Pharmaceuticals Inc | Dennis Podlesak director | $875k 57,600 shares | -27% | |
| 30Weak | Syndax Pharmaceuticals Inc | Keith A. Goldan Chief Financial Officer | $12k 1,296 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.